Clinical Report: The Role of HDL in Cardiovascular Disease
Overview
This editorial discusses the complex role of high-density lipoprotein cholesterol (HDL-C) in cardiovascular disease (CVD), highlighting that simply increasing HDL-C levels has not proven effective in reducing CVD risk. It emphasizes the need for a deeper understanding of HDL's biological functions.
Background
High-density lipoprotein cholesterol (HDL-C) is traditionally viewed as 'good cholesterol' due to its association with lower cardiovascular disease (CVD) risk. However, recent clinical trials and genetic studies challenge this notion, revealing that increasing HDL-C levels does not necessarily correlate with reduced CVD risk. Understanding HDL's multifaceted role is crucial for improving cardiovascular risk assessment.
Data Highlights
No numerical data available in the source material.
Key Findings
Higher HDL-C levels are associated with lower CVD risk, but increasing HDL-C has not effectively reduced CVD in clinical trials.
Clinical trials with niacin and CETP inhibitors raised HDL-C but failed to show a reduction in CVD events.
Composite lipid indices, such as the non-HDL-C/HDL-C ratio, may better predict cardiovascular risk than HDL-C alone.
Genetic studies indicate significant heterogeneity in HDL and its functions, impacting cardiovascular health.
Therapeutic strategies combining PCSK9 inhibitors and statins have been shown to reduce major adverse cardiovascular events.
Clinical Implications
Clinicians should consider the limitations of HDL-C as a standalone marker for cardiovascular risk and explore composite lipid indices for better risk assessment.
Conclusion
The editorial highlights the need for a nuanced understanding of HDL beyond its role as a simple biomarker.
